Article

EGFR immunolabeling pattern may discriminate low-grade gliomas from gliosis

Department of Pathology, University Hospital of Nice, Nice, France.
Journal of Neuro-Oncology (Impact Factor: 2.79). 04/2011; 102(2):171-8. DOI: 10.1007/s11060-010-0308-4
Source: PubMed

ABSTRACT Overexpression of epidermal growth factor receptor (EGFR) is common in gliomas. Gliomas are infiltrating tumors in which neoplastic glial cells can be intermingled with reactive glial cells, particularly in diffuse low-grade gliomas. As overexpression of EGFR has also been described in gliosis, it can be difficult to evaluate EGFR immunolabeling in diffuse low-grade gliomas because of this cell mix. We compared EGFR immunolabeling between gliosis and low-grade gliomas in order to identify distinctive criteria. We studied EGFR expression in 28 cases of gliosis and 39 diffuse low-grade gliomas (23 astrocytomas and 16 oligodendrogliomas). EGFR immunohistochemistry staining was performed on paraffin-embedded sections with a mouse monoclonal antibody (clone 2-18C9; Dako). Co-expression of EGFR with Olig2, Mib-1, and p53 was assessed in seven cases of low-grade gliomas using double immunolabeling. Then, EGFR immunostaining was blindly tested on 22 small specimens of indeterminate glial lesions provided by a reference neuropathological center. Two pathologists of our local center were asked to classify the lesions into diffuse low-grade glioma or gliosis according to the pattern of EGFR expression. Weak expression of EGFR was commonly detected in gliosis (23/28 cases). Strongly-stained cells were absent. Positive cells had reactive glial cell morphology. EGFR expression in gliomas was characterized by constant strongly-stained cells (39/39 cases). All strongly-stained cells had a high nucleus-to-cytoplasm ratio, with minimal to moderate nuclear atypia. Most of the strongly EGFR-positive cells were Olig2-positive. All the cases displayed cells co-expressing EGFR and Mib-1. In three p53-positive tumors, many p53-positive cells were strongly EGFR-positive. On the basis of EGFR expression, 14 out of the 22 indeterminate cases were classified as gliomas and eight as gliosis by both pathologists. Concordance with the initial diagnosis established by the reference center and concordance between the pathologists were 100%. Our results confirm that weak EGFR expression can be detected by immunohistochemistry in gliosis. They show that strong EGFR expression may be specific for neoplastic glial cells. As all low-grade gliomas contained strongly-stained cells in our study, we believe that EGFR immunohistochemistry could be a useful tool for detection of neoplastic glial cells in case of indeterminate glial lesions.

Download full-text

Full-text

Available from: Romane Auvergne, Jun 06, 2014
2 Followers
 · 
192 Views
 · 
218 Downloads
  • Source
    • "For histological examination, the sections were stained using Haematoxylin–Erythrosine–Safran (HES) for morphology analysis and alcyan blue for proteoglycan detection. Indirect immunostaining assay was performed as described previously [17]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Despite the numerous available drugs, the most appropriate treatments for patients affected by common or rare renal cell carcinomas (RCC), like those associated with the Xp11.2 translocation/transcription factor for immunoglobulin heavy-chain enhancer 3 (TFE3) gene fusion (TFE3 RCC), are not clearly defined. We aimed to make a parallel between the sensitivity to targeted therapies on living patients and on cells derived from the initial tumor. Three patients diagnosed with a metastatic RCC (one clear cell RCC [ccRCC], two TFE3 RCC) were treated with anti-angiogenesis drugs. The concentrations of the different drugs giving 50% inhibition of cell proliferation (IC50) were determined with the Thiazolyl Blue Tetrazolium Bromide (MTT) assay on cells from the primary tumors and a reference sensitive RCC cell line (786-O). We considered the cells to be sensitive if the IC50 was lower or equal to that in 786-O cells, and insensitive if the IC50 was higher to that in 786-O cells (IC 50 of 6±1 µM for sunitinib, 10±1 µM for everolimus and 6±1 µM for sorafenib). Based on this standard, the response in patients and in cells was equivalent. The efficacy of anti-angiogenesis therapies was also tested in cells obtained from five patients with non-metastatic ccRCC, and untreated as recommended by clinical practice in order to determine the best treatment in case of progression toward a metastatic grade. In vitro experiments may represent a method for evaluating the best first-line treatment for personalized management of ccRCC during the period following surgery.
    PLoS ONE 03/2014; 9(3):e89449. DOI:10.1371/journal.pone.0089449 · 3.23 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: STAT5 activation in primary glioma was analyzed using antibody directed against phosphorylated STAT5 (pSTAT5), in all samples robust pSTAT5 immunostaining was detected, predominantly in the nucleus. We then used immunofluorescence, transcription factor binding assays and western blotting to study EGF-modulated STAT5 activation in the human U87 glioma cell line. EGF was found to upregulate pSTAT5 levels and enhances STAT5 DNA-binding activity. To address the role of STAT5 in glioma cell invasion, resting and EGF-treated U87 cells were treated with siRNA directed against STAT5 and the extent of glioma cell migration into a Matrigel matrix was monitored. EGF treatment markedly enhanced matrix invasion, and knockdown of STAT5 expression with siRNA significantly downregulated matrix invasion by both EGF-stimulated and resting glioma cells. However, transfection with a decoy oligonucleotide abolished transcriptional activation of a STAT5 target gene but failed to inhibit matrix invasion in resting U87 cells. By contrast, the decoy nucleotide abolished EGF enhancement of matrix invasion. STAT5 therefore promotes glioma cell invasion via at least two different pathways: a pathway dependent of STAT5 DNA binding, and a second pathway independent of STAT5 DNA binding.
    Neuroscience Letters 10/2010; 487(2):228-33. DOI:10.1016/j.neulet.2010.10.028 · 2.06 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Filopodia have been hypothesized to act as remote sensors of the cell environment, but many details of the sensor function remain unclear. We investigated the distribution of the epidermal growth factor (EGF) receptor (EGFR) density on filopodia and on the dorsal cell membrane of A431 human epidermoid carcinoma cells using a nanoplasmonic enabled imaging tool. We targeted cell surface EGFR with 40 nm diameter Au nanoparticles (NPs) using a high affinity multivalent labeling strategy and determined relative NP binding affinities spatially resolved through plasmon coupling. Distance-dependent near-field interactions between the labels generated a NP density (ρ)-dependent spectral response that facilitated a spatial mapping of the EGFR density distribution on subcellular length scales in an optical microscope in solution. The measured ρ values were significantly higher on filopodia than on the cellular surface, which is indicative of an enrichment of EGFR on filopodia. A detailed characterization of the spatial distribution of the NP immunolabels through scanning electron microscopy (SEM) confirmed the findings of the all-optical plasmon coupling studies and provided additional structural details. The NPs exhibited a preferential association with the sides of the filopodia. We calibrated the ρ-dependent spectral response of the Au immunolabels through correlation of optical spectroscopy and SEM. The experimental dependence of the measured plasmon resonance wavelength (λ(res)) of the interacting immunolabels on ρ was well described by the fit λ(res) = 595.0 nm - 46.36 nm exp(-ρ/51.48) for ρ ≤ 476 NPs/μm(2). The performed correlated spectroscopic/SEM studies pave the way toward quantitative immunolabeling studies of EGFR and other important cell surface receptors in an optical microscope.
    ACS Nano 08/2011; 5(8):6619-28. DOI:10.1021/nn202055b · 12.88 Impact Factor
Show more